news
Verily gets NVIDIA AI investment, Oracle launches data intelligence for life sciences
NVIDIA is investing in Verily, Alphabet's life sciences research arm, to use AI for health insights. Separately, Oracle launched a new Life Sciences Data Intelligence platform to handle massive research datasets. This signals bigger moves into how AI and data crunching will redefine drug discovery and personalized health data.
NVIDIA is investing in Verily, Alphabet's life sciences research arm, to use AI for health insights. Separately, Oracle launched a new Life Sciences Data Intelligence platform to handle massive research datasets. This signals bigger moves into how AI and data crunching will redefine drug discovery and personalized health data.
The architecture take
The money flowing into AI for life sciences isn't just about faster drug discovery anymore, it's about making sense of what works for you. Verily, with NVIDIA's muscle, is now better positioned to link genetics, lifestyle, and disease. Think less about a single cure, more about predictive models that nudge your hormones, your sleep, or your nervous system back to baseline before things go sideways. Oracle's move to handle bigger data piles for pharma companies? That's the plumbing behind the scenes, making sure all those numbers can actually talk to each other. I'm watching this because better data integration means future trials could actually tell us what really moves the needle on individual physiology, not just population averages. The real shift isn't the tech itself, it's the shift to truly personalized biology, not just personalized marketing. This is what you pay for.